246 related articles for article (PubMed ID: 9727572)
1. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
Bayoumi AM; Redelmeier DA
AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
Freedberg KA; Cohen CJ; Barber TW
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(4):275-82. PubMed ID: 9292586
[TBL] [Abstract][Full Text] [Related]
5. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
Cohn DL
Drugs; 1997; 54 Suppl 2():8-15; discussion 28-9. PubMed ID: 9358195
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
[TBL] [Abstract][Full Text] [Related]
7. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
Uthman MM; Uthman OA; Yahaya I
Cochrane Database Syst Rev; 2013 Apr; (4):CD007191. PubMed ID: 23633339
[TBL] [Abstract][Full Text] [Related]
8. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease.
Hewitt RG; Papandonatos GD; Shelton MJ; Hsiao CB; Harmon BJ; Kaczmarek SR; Amsterdam D
AIDS; 1999 Jul; 13(11):1367-72. PubMed ID: 10449290
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
[TBL] [Abstract][Full Text] [Related]
10. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
Hoffmann T; Brunner H
Eur J Health Econ; 2004 Jun; 5(2):129-35. PubMed ID: 15452749
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease.
Dautzenberg B
Drugs; 1997; 54 Suppl 2():1-7; discussion 28-9. PubMed ID: 9358194
[TBL] [Abstract][Full Text] [Related]
12. Azithromycin in the prophylaxis of opportunistic infections in AIDS.
McCutchan JA
Int J STD AIDS; 1996; 7 Suppl 1():34-7. PubMed ID: 8652726
[TBL] [Abstract][Full Text] [Related]
13. Rifabutin for MAC questioned.
Posit Aware; 1995; ():6. PubMed ID: 11362571
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques.
Revicki DA; Simpson KN; Wu AW; LaVallee RL
Qual Life Res; 1995 Aug; 4(4):309-18. PubMed ID: 7550179
[TBL] [Abstract][Full Text] [Related]
15. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection.
Fichtenbaum CJ; Zackin R; Feinberg J; Benson C; Griffiths JK;
AIDS; 2000 Dec; 14(18):2889-93. PubMed ID: 11153670
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
17. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
[TBL] [Abstract][Full Text] [Related]
18. Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting.
Mandigo K; Hogg RS; Phillips P; Barber C; Le T; Bessuille E; Black W; O'Shaughnessy MV; Schechter MT; Montaner JS
Tuber Lung Dis; 1996 Jun; 77(3):233-8. PubMed ID: 8758106
[TBL] [Abstract][Full Text] [Related]
19. Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis.
Pozniak A; Nelson MR
Genitourin Med; 1996 Aug; 72(4):269-71. PubMed ID: 8976832
[No Abstract] [Full Text] [Related]
20. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
